title: Association between the ERCC1 rs11615 polymorphism and clinical outcomes of oxaliplatin-based chemotherapies in gastrointestinal cancer: a meta-analysis.
abstract: OBJECTIVE
  The relationship between the excision repair cross-complementing 1 (ERCC1) rs11615 polymorphism (C/T) and responses to oxaliplatin-based chemotherapy for gastric cancer (GC) and colorectal cancer (CRC) patients is controversial. Therefore, we performed a meta-analysis to assess this relationship.
  
  
  METHODS
  Relevant studies were retrieved by searching the PubMed database. A systematic review and meta-analysis was performed to evaluate the predictive value of the ERCC1 rs11615 polymorphism for the clinical outcomes of GC and CRC patients receiving oxaliplatin-based chemotherapy. Therapeutic response to chemotherapy, progression-free survival (PFS), and overall survival (OS) were analyzed.
  
  
  RESULTS
  A total of 22 studies were included in this meta-analysis, including 1,242 cases of GC and 1,772 cases of CRC. For the ERCC1 rs11615 polymorphism, the T allele was associated with a reduced response to chemotherapy in Asians and GC patients (P<0.05). On the other hand, the T allele was associated with a significant increase in the risk for shorter PFS and OS in all patients (PFS: hazard ratio [HR] =1.22, P<0.001, 95% confidence interval [CI] =0.93-1.51 and OS: HR =1.12, P<0.001, 95% CI =0.85-1.40).
  
  
  CONCLUSIONS
  The ERCC1 rs11615 polymorphism was closely associated with the clinical outcomes of GC and CRC patients treated with oxaliplatin-based chemotherapy.
authors.affiliation: Department of Oncology, The First Hospital of Lanzhou University (The Branch Hospital of Donggang), Lanzhou, Gansu Province, People's Republic of China.
authors.forename: Shou-Cheng
authors.initials: SC
authors.lastname: Ma
authors.affiliation: Department of Gastroenterology, The First Hospital of Lanzhou University (The Branch Hospital of Donggang), Lanzhou, Gansu Province, People's Republic of China.
authors.forename: Yue
authors.initials: Y
authors.lastname: Zhao
authors.affiliation: Department of Oncology, The First Hospital of Lanzhou University (The Branch Hospital of Donggang), Lanzhou, Gansu Province, People's Republic of China.
authors.forename: Tao
authors.initials: T
authors.lastname: Zhang
authors.affiliation: Department of Oncology, The First Hospital of Lanzhou University (The Branch Hospital of Donggang), Lanzhou, Gansu Province, People's Republic of China.
authors.forename: Xiao-Ling
authors.initials: XL
authors.lastname: Ling
authors.affiliation: Department of Oncology, The First Hospital of Lanzhou University (The Branch Hospital of Donggang), Lanzhou, Gansu Province, People's Republic of China.
authors.forename: Da
authors.initials: D
authors.lastname: Zhao
keywords: ERCC1 rs11615; colorectal cancer; gastric cancer; meta-analysis; oxaliplatin-based chemotherapy; polymorphism
references.citation: BMC Gastroenterol. 2012 Sep 29;12:137
references.pmid: 23020798
references.citation: Mutat Res. 2014 Jan;759:37-44
references.pmid: 24220697
references.citation: Br J Cancer. 2013 Apr 30;108(8):1695-703
references.pmid: 23549037
references.citation: Clin Cancer Res. 2008 Mar 1;14(5):1291-5
references.pmid: 18316546
references.citation: PLoS One. 2013 Sep 02;8(9):e71994
references.pmid: 24023723
references.citation: Clin Cancer Res. 2011 Mar 15;17(6):1632-40
references.pmid: 21278243
references.citation: PLoS One. 2014 Mar 07;9(3):e90916
references.pmid: 24608110
references.citation: Pharmacogenet Genomics. 2009 Aug;19(8):613-25
references.pmid: 19620936
references.citation: Asian Pac J Cancer Prev. 2012;13(7):3465-9
references.pmid: 22994779
references.citation: Mol Med Rep. 2013 Jun;7(6):1904-11
references.pmid: 23604281
references.citation: Sao Paulo Med J. 2013;131(1):35-8
references.pmid: 23538593
references.citation: Br J Cancer. 2013 Jul 9;109(1):68-75
references.pmid: 23807173
references.citation: Br J Cancer. 2009 Sep 15;101(6):998-1004
references.pmid: 19672255
references.citation: Cancer Sci. 2010 Feb;101(2):530-5
references.pmid: 19922504
references.citation: Cancer Chemother Pharmacol. 2009 Oct;64(5):1001-7
references.pmid: 19247656
references.citation: J Clin Oncol. 2007 Apr 1;25(10):1247-54
references.pmid: 17401013
references.citation: J Gastrointest Oncol. 2014 Feb;5(1):57-66
references.pmid: 24490043
references.citation: Acta Naturae. 2014 Jan;6(1):23-34
references.pmid: 24772324
references.citation: PLoS One. 2013 Dec 26;8(12):e83138
references.pmid: 24386151
references.citation: Tumour Biol. 2014 Apr;35(4):2941-8
references.pmid: 24318989
references.citation: Cancer Sci. 2009 Feb;100(2):278-83
references.pmid: 19068092
references.citation: Clin Cancer Res. 2005 Sep 1;11(17):6212-7
references.pmid: 16144923
references.citation: Ann Oncol. 2010 Mar;21(3):535-9
references.pmid: 19850635
references.citation: Pharmacogenet Genomics. 2013 Nov;23(11):597-604
references.pmid: 23962907
references.citation: J Cancer Res Ther. 2013 Jul-Sep;9(3):410-5
references.pmid: 24125975
references.citation: Cancer Chemother Pharmacol. 2010 Aug;66(3):493-500
references.pmid: 19960344
references.citation: J Clin Oncol. 2009 Jun 10;27(17):2863-73
references.pmid: 19332728
references.citation: J Cancer. 2014 May 02;5(6):425-32
references.pmid: 24847383
references.citation: Pharmacogenomics. 2011 Mar;12(3):433-42
references.pmid: 21449681
references.citation: Int J Cancer. 2010 Dec 15;127(12):2893-917
references.pmid: 21351269
references.citation: Eur J Cancer. 2008 Jun;44(9):1229-37
references.pmid: 18448328
references.citation: Br J Cancer. 2004 Jul 19;91(2):344-54
references.pmid: 15213713
references.citation: World J Gastroenterol. 2008 Nov 7;14(41):6401-7
references.pmid: 19009659
references.citation: Br J Cancer. 2008 Oct 7;99(7):1050-5
references.pmid: 18797464
references.citation: Br J Clin Pharmacol. 2010 Jan;69(1):58-66
references.pmid: 20078613
references.citation: Jpn J Clin Oncol. 2010 Oct;40(10):954-60
references.pmid: 20462983
references.citation: Oncol Rep. 2009 Jul;22(1):127-36
references.pmid: 19513514
references.citation: Oncol Lett. 2013 Sep;6(3):648-654
references.pmid: 24137384
references.citation: BMC Cancer. 2008 May 27;8:148
references.pmid: 18505590
references.citation: Gynecol Oncol. 2013 Aug;130(2):377-82
references.pmid: 23632208